Inclusion of patients with brain metastases in phase I trials: an unmet need.
作者： Mrinal M. Gounder , David R. Spriggs
DOI: 10.1158/1078-0432.CCR-11-0759
关键词: Internal medicine 、 Phase i trials 、 Poor prognosis 、 Population 、 Confounding 、 Oncology 、 Unmet needs 、 Cancer 、 Surgery 、 Medicine
摘要: Patients with brain metastases are increasing in number; however, these patients often excluded phase I/II trials due to perceived poor prognosis, risk of hemorrhage, inefficient drug delivery, and confounding toxicities. Tsimberidou colleagues demonstrate that selected can be appropriately enrolled I have outcomes representative the general cancer population. Clin Cancer Res; 17(12); 3855–7. ©2011 AACR .
aacrjournals.org
sci-hub.se 参考文章(13)
Marc E. Buyse, Elizabeth A Eisenhauer, Christopher Twelves, Phase I Cancer Clinical Trials: A Practical Guide ,(2006)
Apostolia Maria Tsimberidou, Katherine Letourneau, Sijin Wen, Jennifer Wheler, David Hong, Aung Naing, Nancy G. Iskander, Cynthia Uehara, Razelle Kurzrock, Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience Clinical Cancer Research. ,vol. 17, pp. 4110- 4118 ,(2011) , 10.1158/1078-0432.CCR-10-3095
Craig P Carden, Roshan Agarwal, Frank Saran, Ian R Judson, Eligibility of patients with brain metastases for phase I trials: time for a rethink? Lancet Oncology. ,vol. 9, pp. 1012- 1017 ,(2008) , 10.1016/S1470-2045(08)70257-2
Laurie Gaspar, Charles Scott, Marvin Rotman, Sucha Asbell, Theodore Phillips, Todd Wasserman, W.Gillies McKenna, Roger Byhardt, Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials International Journal of Radiation Oncology Biology Physics. ,vol. 37, pp. 745- 751 ,(1997) , 10.1016/S0360-3016(96)00619-0
Stephen J Falk, David J Girling, Roger J White, Penelope Hopwood, Angela Harvey, Wendi Qian, Richard J Stephens, Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial BMJ. ,vol. 325, pp. 465- 465 ,(2002) , 10.1136/BMJ.325.7362.465
Elizabeth R. Gerstner, Robert L. Fine, Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. Journal of Clinical Oncology. ,vol. 25, pp. 2306- 2312 ,(2007) , 10.1200/JCO.2006.10.0677
Isaiah J. Fidler, The role of the organ microenvironment in brain metastasis. Seminars in Cancer Biology. ,vol. 21, pp. 107- 112 ,(2011) , 10.1016/J.SEMCANCER.2010.12.009
Paul R. Lockman, Rajendar K. Mittapalli, Kunal S. Taskar, Vinay Rudraraju, Brunilde Gril, Kaci A. Bohn, Chris E. Adkins, Amanda Roberts, Helen R. Thorsheim, Julie A. Gaasch, Suyun Huang, Diane Palmieri, Patricia S. Steeg, Quentin R. Smith, Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer Clinical Cancer Research. ,vol. 16, pp. 5664- 5678 ,(2010) , 10.1158/1078-0432.CCR-10-1564
Loren K. Mell, James J. Dignam, Joseph K. Salama, Ezra E.W. Cohen, Blase N. Polite, Virag Dandekar, Amit D. Bhate, Mary Ellyn Witt, Daniel J. Haraf, Bharat B. Mittal, Everett E. Vokes, Ralph R. Weichselbaum, Predictors of Competing Mortality in Advanced Head and Neck Cancer Journal of Clinical Oncology. ,vol. 28, pp. 15- 20 ,(2010) , 10.1200/JCO.2008.20.9288
Elizabeth Horstmann, Mary S. McCabe, Louise Grochow, Seiichiro Yamamoto, Larry Rubinstein, Troy Budd, Dale Shoemaker, Ezekiel J. Emanuel, Christine Grady, Risks and benefits of phase 1 oncology trials, 1991 through 2002. The New England Journal of Medicine. ,vol. 352, pp. 895- 904 ,(2005) , 10.1056/NEJMSA042220